Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Ding, X., Wang, X., Wu, J., Zhang, M., & Cui, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01268-9 · Cited by 454
“Pathophysiologically, the current results reflect the previously suggested role of insulin resistance in the pathogenesis of atherosclerosis [8, 10].”
BackgroundInsulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Hong, S.-H., & Choi, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020494 · Cited by 390
“MAPK Family JNK is a member of the MAPK family and is activated by TNF-α, IL-1β, free-fatty acids, ER stress, and LTB4 [66,67].”
BackgroundInfluentialHong, S., Han, K., & Park, C.-Y. (2020) · BMC Medicine · doi:10.1186/s12916-020-01824-2 · Cited by 376
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
Ma, X., Dong, L., Shao, Q., Cheng, Y., Lv, S., Sun, Y., Shen, H., Wang, Z., Zhou, Y., & Liu, X. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01006-7 · Cited by 232
Liu, X.-C., He, G.-D., Lo, K., Huang, Y.-Q., & Feng, Y.-Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.628109 · Cited by 211
Huo, G., Tang, Y., Liu, Z., Cao, J., Yao, Z., & Zhou, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02686-9 · Cited by 167
“Insulin resistance refers to the weakening of the physiological effect of insulin in the body, which is a common pathological mechanism of a variety of metabolic related diseases, and is closely related to the occurrence and development of atherosclerosis [9–11].”
Li, F., Wang, Y., Shi, B., Sun, S., Wang, S., Pang, S., & Wu, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02114-w · Cited by 163
“Evidence from previous studies proved that IR contributed to the pathogenesis of atherosclerosis and was recognized as a notable risk factor for CVD [22–25].”
BackgroundInsulin resistance in ischemic stroke: Mechanisms and therapeutic approaches
Ding, P.-F., Zhang, H., Wang, J., Gao, Y., Mao, J.-N., Hang, C., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1092431 · Cited by 161
Zhou, Z., Liu, Q., Zheng, M., Zuo, Z., Zhang, G., Shi, R., & Wu, T. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02308-w · Cited by 157
Zhao, Q., Zhang, T., Cheng, Y., Ma, Y., Xu, Y.-K., Yang, J., & Zhou, Y.-J. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.59840 · Cited by 139
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 156
Preparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.074 · Cited by 141
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01664-9 · Cited by 118
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Self-citationSun, Y., Yu, C., Ma, S., Mao, Z., Meng, D., Xuan, K., Lu, R., Pan, X., & Zhu, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02835-0 · Cited by 130
“IR serves as a central pathological driver underlying numerous metabolic disorders and critically contributes to CVD pathogenesis through multiple mechanisms [25, 26].”
Ou, H., Wei, M., Li, X., & Xia, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02848-9 · Cited by 127
“The CTI index is calculated according to this formula [23] : CTI = 0.412 × Ln (CRP [mg/L]) + Ln (TG [mg/ dl] × FPG [mg/dl])/2.”
InfluentialHe, H., Xie, Y., Chen, Q., Li, Y., Li, X.-X., Mu, Y.-K., Duo, X., Gao, Y., & Zheng, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02396-8 · Cited by 102
Zhao, Q., Cheng, Y., Xu, Y.-K., Zhao, Z.-W., Liu, C., Sun, T., & Zhou, Y. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01383-7 · Cited by 91
Horton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 105
Yang, X., Wang, G., Jing, J., Wang, A., Zhang, X., Jia, Q., Meng, X., Zhao, X., Liu, L., Li, H., et al. (2022) · BMC Neurology · doi:10.1186/s12883-022-02588-3 · Cited by 77
Xu, J., Kitada, M., Ogura, Y., & Koya, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641852 · Cited by 79
Salekeen, R., Haider, A. N., Akhter, F., Billah, M. M., Islam, M. E., & Islam, K. M. D. (2022) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2022.200143 · Cited by 86
Nam, K., Kwon, H., & Lee, Y.-S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94631-5 · Cited by 75
Wang, B., Jiang, T., Qi, Y., Luo, S., Xia, Y., Lang, B., Zhang, B., & Zheng, S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07639-0 · Cited by 104
Wu, Z., Wang, J., Li, Z., Han, Z., Miao, X., Liu, X., Li, X., Wang, W., Guo, X., & Tao, L. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.027 · Cited by 65
Nutritional guidelines for the management of insulin resistance
Muscogiuri, G., Barrea, L., Caprio, M., Ceriani, F., Chavez, A. O., El Ghoch, M., Frias-Toral, E., Mehta, R. J., Mendez, V., Paschou, S. A., et al. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1908223 · Cited by 63
Endothelial insulin resistance induced by adrenomedullin mediates obesity-associated diabetes
Cho, H., Lai, C.-C., Bonnavion, R., Alnouri, M. W., Wang, S., Roquid, K. A., Kawase, H., Campos, D., Chen, M., Weinstein, L. S., et al. (2025) · Science · doi:10.1126/science.adr4731 · Cited by 75
Cai, X., Hu, J., Zhu, Q., Wang, M., Liu, S., Dang, Y., Hong, J., & Li, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1049211 · Cited by 65
Chen, T., Qian, Y., & Deng, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01893-6 · Cited by 68
“First, IR activates inflammation-related genes and interferes with insulin signaling [31, 32], leading to varying degrees of chronic inflammation, oxidative responses, and endothelial cell dysfunction to damage blood vessels [33, 34], leading to cerebrovascular disease.”
BackgroundScott, D. A., Ponir, C., Shapiro, M. D., & Chevli, P. A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100676 · Cited by 75
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Silveira, É. A., Filho, R. R. D. S., Spexoto, M. C. B., Haghighatdoost, F., Sarrafzadegan, N., & de Oliveira, C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094339 · Cited by 63
“High levels of insulin, in turn, sensitize smooth vascular cells to proliferate via the MAPK pathway [43] and interfere with the control of blood pressure exercised by the renin– angiotensin–aldosterone system [44].”
BackgroundQian, T., Sheng, X., Shen, P., Fang, Y., Deng, Y. L., & Zou, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1224967 · Cited by 57
Zhang, H., Tu, Z., Liu, S.-H., Wang, J., Shi, J., Li, X., Shi, R., Chen, M., Yue, T., Luo, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02576-0 · Cited by 69
Si, Y., Fan, W., Han, C., Liu, J., & Sun, L. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.05.001 · Cited by 57
Wang, A., Tian, X., Zuo, Y., Zhang, X., Wu, S., & Zhao, X. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.019 · Cited by 55
Tian, X., Chen, S., Xu, Q., Xia, X., Zhang, Y., Wang, P., Wu, S., & Wang, A. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02073-2 · Cited by 59
“Cumulative IR accelerated the progression of atherosclerosis by altering risk factors and disrupting metabolism through oxidative stress and inflammation [34–36].”
BackgroundKalinovich, A., Dehvari, N., Åslund, A., van Beek, S., Halleskog, C., Olsen, J., Forsberg, E., Zacharewicz, E., Schaart, G., Rinde, M., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05171-y · Cited by 54
Wang, C., Cai, Z., Deng, X., Li, H., Zhao, Z., Guo, C. Y., Zhang, P., Li, L., Gu, T., Yang, L., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.62010 · Cited by 56
“Accumulation of toxic lipid metabolites in β cell and arterial tissues contributed to insulin resistance and accelerated atherosclerosis in T2DM[37, 38].”
BackgroundLee, J., Jeon, S., Joung, B., Lee, H. S., & Kwon, Y. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319200 · Cited by 55
Digital Health Coaching for Type 2 Diabetes: Randomized Controlled Trial of Healthy at Home
Azelton, K. R., Crowley, A. P., Vence, N., Underwood, K., Morris, G., Kelly, J., & Landry, M. J. (2021) · Frontiers in Digital Health · doi:10.3389/fdgth.2021.764735 · Cited by 49
“Targeting insulin resistance may decrease both micro- and macrovascular complications of T2DM (15, 23), thus addressing the rising cost and burden of this disease.”
BackgroundInsulin Resistance and High Blood Pressure: Mechanistic Insight on the Role of the Kidney
Brosolo, G., Porto, A. D., Bulfone, L., Vacca, A., Bertin, N., Scandolin, L., Catena, C., & Sechi, L. A. (2022) · Biomedicines · doi:10.3390/biomedicines10102374 · Cited by 66
Yi, J., Qu, C., Li, X., & Gao, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02437-2 · Cited by 55
Jung, M., Yi, S., An, S. J., Yi, J., Ihm, S., Han, S., Ryu, K.-H., Jung, H. O., & Youn, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01490-z · Cited by 54
“Thus, nitric oxide deficiency in insulin resistance could lead to insufficient vasodilation, inflammation, glucotoxicity, and lipotoxicity, resulting in a vicious cycle [40, 41].”
BackgroundHypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children
Tagi, V. M., Mainieri, F., & Chiarelli, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105814 · Cited by 50
Shared Mechanisms between Cardiovascular Disease and NAFLD
Huang, D. Q., Downes, M., Evans, R. M., Witztum, J. L., Glass, C. K., & Loomba, R. S. (2022) · Seminars in Liver Disease · doi:10.1055/a-1930-6658 · Cited by 47
Guo, X., Shen, R., Yan, S., Su, Y.-N., & Ma, L. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01779-7 · Cited by 52
Martínez‐Sánchez, F. D., Vargas-Abonce, V. P., Guerrero-Castillo, A. P., Santos-Villavicencio, M. D. L., Eseiza-Acevedo, J., Meza-Arana, C. E., Gulías-Herrero, A., & Gómez-Sámano, M. Á. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.006 · Cited by 48
Zheng, D., Cai, J., Xu, S., Jiang, S., Li, C., & Wang, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1471535 · Cited by 51
“Recently, insulin resistance (IR), which is the dysfunction to utilize insulinoftissuecellsandalwaysaccompanyhyperinsulinemia,hasbeen proven to be associated with lots of metabolic diseases, including CVD, dyslipidemia, obesity, and type 2 diabetes (6 – 9).”
BackgroundPreparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C., Pfotenhauer, K., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 45
“Food and Drug Administration has not approved it for this indication (51,52).”
BackgroundTai, S., Fu, L., Zhang, N., Zhou, Y., Xing, Z., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.858209 · Cited by 51
Roles of circular RNAs in diabetic complications: From molecular mechanisms to therapeutic potential
Zhang, J., & Sun, H. (2020) · Gene · doi:10.1016/j.gene.2020.145066 · Cited by 47
Jiang, Z.-Z., Zhu, J., Shen, H., Zhao, S., Tang, Y., Shao-qi, T., Liu, X., & Jiang, T.-A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.832491 · Cited by 44
Rattanatham, R., Tangpong, J., Chatatikun, M., Sun, D., Kawakami, F., Imai, M., & Klangbud, W. K. (2023) · PeerJ · doi:10.7717/peerj.15463 · Cited by 52
“Insulin resistance has been found to play a signi fi cant causal role in developing hypertension ( Brosolo et al., 2022 ) and cardiovascular diseases ( Di Pino & DeFronzo, 2019 ).”
BackgroundHan, R., Zhang, Y., & Jiang, X. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s362248 · Cited by 53
Atherosclerosis and Insulin Resistance: Is There a Link Between Them?
Brie, A. D., Christodorescu, R., Popescu, R., Adam, O., Tîrziu, A., & Brie, D. M. (2025) · Biomedicines · doi:10.3390/biomedicines13061291 · Cited by 58
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 52
Quantitative Perfusion Imaging with Total-Body PET
Knuuti, J. M., Tuisku, J., Kärpijoki, H., Iida, H., Maaniitty, T., Latva‐Rasku, A., Oikonen, V., Nesterov, S. V., Teuho, J., Jaakkola, M. K., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264870 · Cited by 51
Marco, M. D., Scilletta, S., Miano, N., Capuccio, S., Musmeci, M., Mauro, S. D., Filippello, A., Scamporrino, A., Bosco, G., Barbagallo, F. D. G., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112189 · Cited by 42
Xiong, S., Chen, Q., Zhang, Z., Chen, Y., Hou, J. W., Cui, C., Cheng, L.-C., Su, H., Yu, L., Yang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01553-1 · Cited by 43
“Insulin resistance (IR), a characteristic feature of T2DM, has been demonstrated to be significantly associated with the occurrence, progression, and prognosis of atherosclerotic cardiovascular disease [2].”
BackgroundDing, L., Fu, B., Zhang, H., Dai, C., Zhang, A., Yu, F., Mi, L., Hua, W., & Tang, M. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-04992-5 · Cited by 46
Tang, N., Chen, X., Li, H., Cheng, S., Hu, Y., Wang, L., Zhou, Q., Zhang, Q., Ji, H., & Qi, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-10184-x · Cited by 56
“Concurrently, insulin resistance contributes to metabolic dysregulation, promoting hyperglycemia, dyslipidemia, and hypertension, all of which synergistically exacerbate cardiovascular risk 19,20 .”
Ruan, X., Ling, Y., Chen, J., Xiang, Y., Ruan, H., Zhang, W., Jing, L., Gao, X., He, Y., Lu, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02939-7 · Cited by 53
Sato, F., Nakamura, Y., Kayaba, K., & Ishikawa, S. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.05.002 · Cited by 42
Liu, C., Liu, X., Ma, X., Cheng, Y., Sun, Y., Zhang, D., Zhao, Q., & Zhou, Y. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00915-9 · Cited by 48
Pino, A. D., Urbano, F., Scicali, R., Mauro, S. D., Filippello, A., Scamporrino, A., Piro, S., Purrello, F., & Rabuazzo, A. M. (2019) · Cells · doi:10.3390/cells8080910 · Cited by 38
Colca, J. R., & Scherer, P. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101409 · Cited by 41
“Some have argued for a broader use of pioglitazone because of its potential to prevent the loss of pancreatic b cell function and in particular, its efficacy in reducing cardiovascular disease, which remains the major cause of morbidity and mortality in both diabetic and prediabetic patients [17,18].”
BackgroundWang, Y., Karmakar, T., Ghosh, N., Basak, S., & Gopal Sahoo, N. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2021.131376 · Cited by 35
Role of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications
Pan, Y., Zhao, M., Song, T., Tang, J., Kuang, M., Liu, H., & Zhong, S. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s478287 · Cited by 42
Tao, S., Yu, L., Li, J., Xie, Z., Huang, L., Yang, D., Tan, Y., Zhang, W., Huang, X., & Xue, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02060-7 · Cited by 35
“Insulin resistance (IR) is a clinical state of impaired insulin sensitivity which may lead to cardiometabolic alterations such as hyperglycemia, dyslipidemia, and hypertension [11, 12].”
BackgroundAre thiazolidinediones a preferred drug treatment for type 2 diabetes?
Hurren, K. M., & Dunham, M. W. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1853100 · Cited by 35
Xu, Y., Pu, S., Zhang, Y., Tong, X., Sun, X., Shan, Y., & Gao, X. (2023) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14344 · Cited by 35
Yao, J., Zhou, F. L., Ruan, L., Liang, Y., Zheng, Q., Shao, J., Cai, F., Zhou, J., & Zhou, H. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13595 · Cited by 35
“6,21 22 – 24 Existing large-scale nationwide studies have shown a significant correlation between IR assessed by eGDR and stroke function outcomes in patients with a first acute ischemic stroke.”
BackgroundVasyutina, M. L., Alieva, A. S., Reutova, O., Bakaleiko, V. V., Murashova, L. A., Dyachuk, V. A., Catapano, A. L., Baragetti, A., & Magni, P. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155138 · Cited by 34
Moughaizel, M., Dagher, E., Jablaoui, A., Thorin, C., Rhimi, M., Desfontis, J., & Mallem, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264215 · Cited by 39
“Besides its well established relation with dyslipidemia, atherosclerosis has also been reported to have a strong connection with IR [56, 57].”
BackgroundZhang, H., Huang, S., Fang, Y., Zhang, H., Yang, W., & Yu, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02860-z · Cited by 37
Mousa, R. F., Smesam, H. N., Qazmooz, H. A., Al‐Hakeim, H. K., & Maes, M. H. J. (2021) · CNS Spectrums · doi:10.1017/s1092852921000432 · Cited by 34
Barrea, L., Vetrani, C., Caprio, M., Ghoch, M. E., Frías-Toral, E., Mehta, R. J., Méndez, V., Moriconi, E., Paschou, S. Α., Pazderska, A., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1980766 · Cited by 34
“ADA American Diabetes Association AP alkaline phosphatase CV cardiovascular CVD cardiovascular disease DF dietary fiber eGFR glomerular filtration rate FA fatty acids GE gastric emptying GLP-1 glucagon-like peptide GI glycemic index GI gastrointestinal GL glycemic load HbA1c glycated hemoglobin HCD high-carbohydrate d…”
BackgroundInfluentialDiabetic Neuropathy of the Retina and Inflammation: Perspectives
Мухаррамовна, Б. Г., Oshitari, T., & Bikbov, M. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119166 · Cited by 33
“Insulin resistance induced by hyperglycemia and obesity also converges with inflammation and immune modulation in the insulin receptor substrate 1 (IRS-1)/mitogen-activated protein kinase (MAPK)/Akt/phosphatidylinositol-3 kinase (PI3K) and NF-κB/IL-1β/TNF-α/interferon-γ (IFN-γ) pathways [18,43].”
BackgroundWu, T., Chou, C., Cheng, C.-F., Lu, S.-X., & Wang, L. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.10.005 · Cited by 35
Zhang, Y., Chu, C., Zhong, Z., Luo, Y., Ning, F.-F., & Guo, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1101952 · Cited by 33
“As one of the major risk factors for CVD, DM may be treated with hypoglycemic medications such as sodium-dependent glucose transporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonist to lower cardiovascular events (28).”
BackgroundInfluentialTriglyceride-glucose index predicts death in patients with stroke younger than 65
Liu, R., Li, L., Wang, L., & Zhang, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1198487 · Cited by 31
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
Huang, X., Cheng, H., Yuan, S., Ling, Y., Tan, S., Tang, Y., Niu, C., & Lyu, J. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-04420-0 · Cited by 28
“IR is a metabolic condition characterized by an impaired response of target tissues to insulin, resulting in abnormal glucose and lipid metabolism [11–13].”
BackgroundWang, Y., Liu, T., Li, Y., Zhang, K., Fan, H., Ren, J. L., Li, J., Li, Y., Li, X., Wu, X., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01823-6 · Cited by 27
“IR contributes to the development of lipid disorders [27] and accelerates the production of connective tissue in the vessel wall and the aggregation of LDL-C into the arterial smooth muscle [28].”
BackgroundRisk factors for carotid plaque formation in type 2 diabetes mellitus
Chen, J., Li, W., Cao, J., Lu, Y., Wang, C., & Lu, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04836-7 · Cited by 33
“IR has been proved to be common before the onset of T2DM and plays an important role in the occurrence and development of AS [23, 24].”
Backgroundde la Monte, S. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230555 · Cited by 32
“Insulinresistanceisastrongpredictorof atherosclerosis and arteriosclerosis due to injury and stress mediated by high, possibly toxic local levels of insulin [140].”
Liang, P., Mao, L., Ma, Y., Ren, W., & Yang, S. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114234 · Cited by 28
Seifi, N., Nosrati, M., Koochakpoor, G., Aghasizadeh, M., Bahari, H., Namdar, H. B., Afkhami, N., Darban, R. A., Azarian, F., Ferns, G. A., et al. (2024) · Nutrition Journal · doi:10.1186/s12937-023-00904-2 · Cited by 29
“Insulin resistance may take several years to evolve into type 2 diabetes [18].”
BackgroundJiang, X., Wang, W., Lei, L., Feng, T., Hu, Y., Liu, P., Li, Y., Sheng, R., Zhang, Y., Li, S., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93465 · Cited by 29
“Atherosclerosis is a complex disease process, and it is related to metabolic disorders of lipid and glucose [40], hypercholesterolemia [41], inflammation, insulin resistance [42, 43], endothelial dysfunction, fatty liver [44], and so on.”
BackgroundLonardo, A., & Weiskirchen, R. (2025) · Biomolecules · doi:10.3390/biom15121745 · Cited by 37
Li, M., Li, L., Qin, Y., Luo, E., Wang, D., Qiao, Y., Tang, C., & Yan, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.817176 · Cited by 28
Liu, F., Wang, Y., & Yu, J. (2023) · Human Immunology · doi:10.1016/j.humimm.2023.06.002 · Cited by 33
Bell, D. S. H., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15222 · Cited by 35
Kale, D., Fatangare, A., Phapale, P. B., & Sickmann, A. (2023) · Cells · doi:10.3390/cells12242796 · Cited by 25
“Dyslipidemia and hypertension [9,10] are the two main independent risk factors for ASCVD; other risk factors include insulin resistance, hyperglycemia, and obesity [11,12].”
BackgroundXu, Y., Chen, S., Zhu, J., Wang, Q., Li, W., Pan, G., Lv, T., Huang, Y., & Qu, W. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05143-3 · Cited by 28
“It also contributes to the development of metabolic syndrome and accelerates atherosclerosis [42] while simultaneously triggering inflammation and oxidative stress, both linked to increased stroke incidence [40].”
Zhang, X., Yu, C., Ye, R., Liu, T., & Chen, X. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14449 · Cited by 26
Impact of Non-Pharmacological Interventions on the Mechanisms of Atherosclerosis
Matei, D., Buculei, I., Luca, C. M., Corciovă, C., Andriţoi, D., Fuior, R., Iordan, D. A., & Onu, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169097 · Cited by 30
“The molecular etiology of insulin resistance directly contributes to the development of atherosclerotic cardiovascular disease through the inhibition of nitric oxide production and stimulation of the Mitogen-Activated Protein Kinase (MAPK) pathway [95].”
Background
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.